Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC

Chen, Jing; Alduais, Yaser; Chen, Baoan

doi:10.1177/09636897211041587

Cited by 5 publications

(4 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although PD-1 inhibitors have shown many potential advantages in the treatment of NSCLC, there are also some adverse reactions that may occur in patients. Common adverse events include skin-related reactions like rash, itching, and vitiligo, as well as systemic adverse reactions like fatigue, nausea, and muscle and joint pain ( Chen J. et al, 2021 ; Curkovic et al, 2024 ). Therefore, close monitoring of patients’ adverse reactions and timely implementation of corresponding treatment measures are necessary when using PD-1 inhibitors to treat NSCLC.…”

Section: The Mechanism Of Action Of Pd-1 Inhibitors and Their Clinica...mentioning

confidence: 99%

The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance

Liu,

Lei,

Guo

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Recent studies have revealed that sarcopenia can adversely affect the efficacy of PD-1 inhibitors in the treatment of non-small cell lung cancer (NSCLC). PD-1 inhibitors are immune checkpoint inhibitors widely used in the treatment of various cancers. However, NSCLC patients may have poorer outcomes when receiving PD-1 inhibitor treatment, and sarcopenia may affect the efficacy of PD-1 inhibitors through immune and metabolic mechanisms. In this article, we summarize the reported negative impact of sarcopenia on the effectiveness of PD-1 inhibitors in the treatment of NSCLC in recent years. Based on existing research results, we analyze the possible mechanisms by which sarcopenia affects the efficacy of PD-1 inhibitors and discuss possible strategies to address this issue. This could help to understand the impact of sarcopenia on the treatment of PD-1 inhibitors and provide more accurate expectations of treatment outcomes for clinicians and patients. Additionally, we present tailored intervention strategies for sarcopenic patients undergoing PD-1 inhibitor therapy, aiming to optimize treatment efficacy and enhance patient quality of life. Nevertheless, further research is warranted to elucidate the mechanisms through which sarcopenia impacts PD-1 inhibitors and to identify more efficacious intervention approaches for improving the effectiveness of PD-1 inhibitor treatment in sarcopenic patients.

show abstract

Section: The Mechanism Of Action Of Pd-1 Inhibitors and Their Clinica...mentioning

confidence: 99%

The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance

Liu,

Lei,

Guo

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Inhibition of epidermal growth factor receptor (EGFR) using erlotinib, gefitinib, entrectinib, afatinib, dacomitinib, and icotinib and anaplastic lymphoma kinase (ALK) using alectinib, brigatinib, ceritinib, crizotinib, and lorlatinib can stop or slow the growth of NSCLC [51,60,61]. Atezolizumab, avelumab, durvalumab, cemiplimab, nivolumab, and pembrolizumab are monoclonal antibodies used for immunotherapy of NSCLC [62][63][64]. Although these therapies are significant for the management of NSCLC, the side effects remain a concern for cancer care [11,65].…”

Section: Conventional Therapeuticmentioning

confidence: 99%

Exosomes as Nanocarriers for Theragnostic miRNA Markers in Nonsmall Cell Lung Cancer Therapy

Jiang

Ding

et al. 2022

Journal of Nanomaterials

View full text Add to dashboard Cite

Nonsmall cell lung carcinoma (NSCLC) is the leading cause of deaths related to carcinomas of lung by the involvement of several risk factors. Tumor cells, in general, exude larger quantities of biological macromolecules in comparison to their noncancerous opposites. Vesicular bodies or cavities created by the folding back of endosome membranes mingle with the plasma membrane and result in the release of exosomes into the extracellular space after which they enter proximal or distant cells of target. Exosomes are nanovesicles that can carry microRNAs (miRNAs) and other such macromolecules as cargos into the tumor environment by means of cell-to-cell communication. These materials transported by exosomes can act as indicators for oncogenesis and metastasis and result in resistance among therapy-sensitive cancer cells. The cargos inside the vesicles loaded with miRNAs vary according to their particular state and therefore can act as potential prognostic or diagnostic markers for a variety of diseases including lung cancer, especially NSCLC. Although the roles of exosomal miRNAs are unclear or contradictory, the possibility of using exosomes as efficient nanovesicles for the treatment of NSCLC using biological molecules such as miRNA remains critical. Hence, this review focuses on the roles of exosomal and cell-free miRNA in NSCLC therapy at preclinical and clinical levels.

show abstract

“…Immune-related mechanisms play an important role in the development of cancer, especially the level of immune cell infiltration [ 3 ]. Programmed death ligand 1 (PD-L1/CD274), a major immune checkpoint, is often expressed in several types of malignant tumors and related to survival and tumor progression [ 4 ]. Immunotherapy, represented by blockade of PD-1/PD-L1 pathway, has shown good antitumor effects and becomes the first-line therapy for lung cancer [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of RILPL2 and its correlation with tumor immune microenvironment and glycolysis in non-small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Rab-interacting lysosomal protein – like 2 (RILPL2) has been reported to be associated with prognosis and tumor biological functions in breast cancer and endometrial carcinoma. However, its expression and functional role in non-small cell lung cancer (NSCLC) remain unclear. The expression and clinical data of lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) were downloaded from the TCGA database. The expression of RILPL2 in NSCLC cell lines was verified by the Western blot. We used online databases and bioinformatics analysis tools to explore its prognostic value, potential biological functions, and correlations with tumor immune microenvironment.The expression of RILPL2 was significantly lower in NSCLC compared with adjacent normal tissues. Low RILPL2 expression was associated with worse overall survival (OS) in NSCLC. The GO analysis showed RILPL2 was comprehensively involved in immune activity. RILPL2 expression was significantly positively correlated with the infiltration levels of B cells, CD8+T cells, CD4+T cells, macrophages, neutrophils, dendritic cells (P < 0.001), and it was also significantly positively correlated with programmed cell death ligand 1 (PD-L1/CD274) (P < 0.001). High RILPL2 expression could predict better immunotherapy response and prognosis in the immunotherapy cohort. The GSEA analysis showed low RILPL2 expression was associated with glycolysis process in LUAD, which was verified in vitro.These results showed RILPL2 expression was correlated with prognosis, tumor microenvironment, and immunotherapy response in NSCLC. Besides, RILPL2 may regulate glycolysis in LUAD.

show abstract

Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC

Cited by 5 publications

References 111 publications

The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance

The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance

Exosomes as Nanocarriers for Theragnostic miRNA Markers in Nonsmall Cell Lung Cancer Therapy

Prognostic value of RILPL2 and its correlation with tumor immune microenvironment and glycolysis in non-small cell lung cancer

Contact Info

Product

Resources

About